1.36
-1.81%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pulmatrix
From its filings with the US Securities and Exchange Commission
Pulmatrix is based in Framingham, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PULM. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2024, it reported revenue of $7.8m.
Agreement was unanimously approved by our board of directors, which resolved to recommend approval of the Merger Agreement to our stockholders.
Zealand, Russia, Hong Kong and the United States that cover certain formulations and methods of use relevant to our PUR3100 program.
We have successfully formulated iSPERSE™-based products with dual and triple API combinations.
2021, have been poorly adopted due to incomplete efficacy and intolerability of nasal inhalation in patients during a migraine.
All doses of PUR3100 were associated with mean Cmax above the minimum level required to achieve efficacy (1000 pg/mL).
In pre-clinical studies, RV1162 demonstrated direct anti-inflammatory activity in a model of viral induced respiratory inflammation.
RV1162 also demonstrated a reduction in corticosteroid-resistant inflammatory responses in a model of cigarette smoke induced inflammation.
Long-term toxicology studies with RV1162 as a lactose blend suggested that this formulation was not suitable for chronic dosing.
MAP kinase inhibitor being developed by Mereo BioPharma. BCT-197 completed Phase 2 development as first-line therapy for severe AECOPD.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 21 Mar 2014
- Employees
- 2
- Website
- pulmatrix.com ↗
- Head office
- 945 CONCORD STREET, FRAMINGHAM, MA, 01701
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Michael HigginsIndependent Chairman of the Board$85,000
- Mr. Peter LudlumInterim Chief Executive Officer and Interim Chief Financial Officer$780,877
- Dr. Richard BatyckyIndependent Director$54,000
- Mr. Todd BazemoreIndependent Director$52,500
- Dr. Christopher CabellIndependent Director$61,500
- Mr. Anand VaradanIndependent Director$40,000
- Mr. Timothy McCarthyInvestor Relations, since 2019
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pulmatrix Inc develops innovative inhaled therapies using iSPERSE technology for respiratory diseases.
- Pulmatrix has five therapeutic candidates including Pulmazole and PUR1800 for respiratory conditions.
- Pulmatrix employs 22 full-time employees focused on clinical stage biotechnology research.
Weaknesses
- Pulmatrix has only 22 employees which may limit research and development capacity.
- Pulmatrix's IPO in 2014 may indicate limited financial resources for expansion.
- Pulmatrix's clinical stage status requires significant future funding for product development.
Opportunities
- Pulmatrix can expand its iSPERSE technology to new respiratory disease markets.
- Pulmatrix may partner with larger pharmaceutical companies for drug development.
- Pulmatrix can leverage its dry powder delivery technology for systemic applications.
Threats
- Pulmatrix faces competition from established pharmaceutical companies in respiratory treatments.
- Pulmatrix's clinical stage products require successful trials to reach market.
- Pulmatrix must secure ongoing funding to continue development of its therapeutic candidates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.